Pharming’s Q2 earnings show a revenue dip, but the company’s rare disease strategy is gaining momentum—RUCONEST holds steady at 93% active patients, Joenja surges 40% YoY, and a pipeline with two potential billion-dollar opportunities positions Pharming for explosive growth. Despite lowering full-year revenue and operating expense guidance, the company remains confident, citing renewed patient adoption, disciplined cost management, and a pivotal phase two study for leniolisib expected in Q4 that could unlock massive market potential.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
